GLP-1 receptor agonist or SGLT2 inhibitor prescribing became more common for people with type 1 diabetes in recent years, a nationwide cross-sectional analysis found. From 2010 to 2023, the percentage ...

Two classes of diabetes drugs may also improve cardiovascular and kidney disease outcomes in people with or without diabetes. In a meta-analysis involving more than 70,000 patients with diabetes, ...

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors — a class of drugs used to treat type 2 diabetes — could also prevent dementia, according to a study published Wednesday in The BMJ. The authors ...

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of diabetes drugs also known as gliflozins, could lower the risk for dementia and Parkinson’s disease, a new study finds. The report was ...

The weight-loss drug Ozempic can help reduce stroke patients' risk of a heart attack or death, a new study says. GLP-1 weight-loss drugs like Ozempic or SGLT2 diabetes medications like Jardiance or ...

A recent review examined how widely used treatments such as metformin, SGLT2 inhibitors, and GLP-1 receptor agonists may affect cancer growth.

A large population-based study found that adults with type 2 diabetes (T2D) who start treatment with sodium–glucose ...

Common diabetes drugs may do more than regulate blood sugar—they could also influence how cancers grow, spread, or slow down.

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

Share on Pinterest Popular diabetes drugs have been linked with a lower risk of experiencing a second stroke or a heart attack. Image credit: andresr/Getty Images. About 12.2 million new strokes are ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SGLT2 inhibitors ...